CompletedPhase 1NCT03886701

Doravirine, Rifapentine and Isoniazid Interaction

Studying Tuberculosis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Walter K. Kraft
Principal Investigator
Walter K Kraft, MD
Sidney Kimmel Medical College at Thomas Jefferson University
Intervention
Doravirine (DOR)(drug)
Enrollment
11 enrolled
Eligibility
18-60 years · All sexes
Timeline
20192019

Study locations (1)

Collaborators

Merck Sharp & Dohme LLC

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03886701 on ClinicalTrials.gov

Other trials for Tuberculosis

Additional recruiting or active studies for the same condition.

See all trials for Tuberculosis

← Back to all trials